You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 5, February 5, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (11)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Related article
 •Similar articles in JAMA

Prevention of Contrast Nephropathy

Gary C. Curhan, MD, ScD

JAMA. 2003;289:606-608.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Contrast nephropathy is one of the well-recognized risks of coronary angiography. Although the disease occurs infrequently with normal renal function, its frequency increases with decreasing renal function, ranging from 5% in patients with mild renal insufficiency1 to 50% in those with severe renal dysfunction and diabetes.2 Given that contrast nephropathy is associated with increased morbidity, mortality, and length of hospitalization, and possibly with long-term renal impairment,3 there is great interest in its prevention.

Several factors increase the risk of contrast nephropathy. Contrast-related factors include higher total dose and the use of ionic and high osmotic agents.3 Patient-related risk factors include renal dysfunction, diabetes mellitus, congestive heart failure, and reduced effective circulating volume.3

The mechanism by which contrast adminstration leads to renal injury is uncertain. Studies in humans suggest 2 potential pathways that may operate individually or together: renal vasoconstriction, resulting in medullary ischemic damage, and . . . [Full Text of this Article]

Author Affiliations: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.


RELATED LETTER

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Albert Yuh-Jer Shen
JAMA. 2003;289(21):2794-2795.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention: A Randomized Controlled Trial
Jay Kay, Wing Hing Chow, Tak Mao Chan, Sing Kai Lo, On Hing Kwok, Alex Yip, Katherine Fan, Chi Hang Lee, and Wai Fai Lam
JAMA. 2003;289(5):553-558.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC Risk Score
Halkin et al.
J Am Coll Cardiol 2005;45:1397-1405.
ABSTRACT | FULL TEXT  

N-Acetylcysteine for the Prevention of Radiocontrast Induced Nephropathy: A Meta-Analysis of Prospective Controlled Trials
Kshirsagar et al.
J. Am. Soc. Nephrol. 2004;15:761-769.
ABSTRACT | FULL TEXT  

Contrast Nephropathy
Rezkalla
Clin Med Res 2003;1:301-304.
ABSTRACT | FULL TEXT  

Acetylcysteine and Renal Function Following Coronary Angiographic Procedures
Shen
JAMA 2003;289:2794-2795.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.